xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

368

KUANetal.

TABLE XXXII.4 (Continued)

Clinical endpoints Treatment toxicities

Study

Year LOE Study design Study groups

Conclusion

Bonner et al. 2177

1. There were higher rates of grade 3 + acneiform-rash in the CRT group 2. There was no difference in rates of other grade 3 + toxicities 1. The most common grade 3 + toxicities were neutropenia, nausea/vomiting, mucositis, diarrhea, anemia, and thrombocytopenia 2. Grade 5 febrile neutropenia occurred in 6% of patients 1. QOL declined during treatment but rose back to baseline by 1 month after treatment and superior to baseline at 3 months 2. Symptom interference decreased over time after treatment 3. Symptom burden initially increased during treatment but declined back to pretreatment levels at 1 and 3 months posttreatment 4. “Hope” remained steady throughout the study 1. At a median of 9 months after treatment, 64% of patients experienced AEs, most frequently fatigue, rash, pruritis, and appetite decrease, and 13% of patients experienced grade 3/4 AEs, most commonly ALT and AST elevations immune-related AEs were hypothyroidism (28 patients, two of which were grade 3) and pneumonitis (five patients, two grade 3) 1. 63% of patients had AEs of any grade, most commonly fatigue, pruritis, nausea, decreased appetite, and rash 2. 17% of patients had grade 3/4 AEs, most commonly elevated AST or ALT, or hyponatremia 2. The most common

2006 2

RCT

424 patients with

locally advanced head and neck cancer treated with RTalone ( n = 213) versus CRT with cetuximab ( n = 211)

Bernadach et al. 2172

2021

3

Retrospective cohort

113 patients treated with IC with TPF

Treatment toxicities

Tsanet al. 2174

QOL, symptoms, andhopeas measured by the FACT-HN, MDASI, and HHI, pre-, during, and posttreatment

2021

3

Prospective cohort

54 adults with head and neck cancer treated with CRT

Mehra et al. 2187

2018 3

Prospective cohort

192 patients receiving pembrolizumab for recurrent, metastatic, or persistent HNSCC

Treatment related AEs

Seiwert et al. 2183

Drug-related AEs

2016 3

Prospective cohort

60 patients with

PD-L1-positive head and neck cancer treated with pembrolizumab

(Continues)